Financial Reports
Related Searches:
Filter by:
271 - 285 of 673 results
October 20, 2010
Growth in the quarter was driven by worldwide pharmaceutical sales, up 22% to $4.9 billion.
Read More »
October 20, 2010
Product sales were up 13% to $1.9 billion in the quarter. Antiviral product sales were $1.7 billion (+12%).
Read More »
October 19, 2010
Worldwide Pharmaceutical sales were $5.5 billion in the quarter (+5%), with operational growth of 6% and a negative impact from currency of 1%.
Read More »
October 14, 2010
Pharmaceutical sales were up 2% attributed to Avastin, MabThera/Rituxan, Herceptin, Lucentis, Actemra/RoActemra and Xeloda.
Read More »
September 15, 2010
Life Sciences sales accounted for $335.4 million in the quarter, up 5%.
Read More »
September 9, 2010
Revenues from commercial manufacturing operations were down 2% to $130.2 million.
Read More »
August 10, 2010
Clinical Research Services revenue in the quarter was $225.4 million (+11%).
Read More »
August 5, 2010
Service revenues are down, but new business awards jumped from 1Q10.
Read More »
August 3, 2010
Revenues in the quarter were favorably impacted by $5.4 billion (most of the 58% revenue bump), due to the addition of the legacy Wyeth products.
Read More »
August 3, 2010
Pharmaceutical Packaging Systems sales were $200.9 million in the quarter (+6%) attributed to growth in sales of Westar-processed, FluroTec- and Teflon-coated products, as well as sales of Envision.
Read More »
August 2, 2010
Total product sales for the quarter were $3.6 billion (-1%). Sales in the U.S. totaled $2.8 billion (-2%) and International sales were up 3% to $826 million.
Read More »
271 - 285 of 673 results
